Two calix[4]pyrroles as potential therapeutics for castration-resistant prostate cancer.
Invest New Drugs
; 40(6): 1185-1193, 2022 12.
Article
en En
| MEDLINE
| ID: mdl-35976541
ABSTRACT
Macrocyclic compounds meso-(p-acetamidophenyl)-calix[4]pyrrole and meso-(m-acetamidophenyl)-calix[4]pyrrole have previously been reported to exhibit cytotoxic properties towards lung cancer cells. Here, we report pre-clinical in vitro and in vivo studies showing that these calixpyrrole derivatives can inhibit cell growth in both PC3 and DU145 prostatic cancer cell lines. We explored the impact of these compounds on programmed cell death, as well as their ability to inhibit cellular invasion. In this study we have demonstrated the safety of these macrocyclic compounds by cytotoxicity tests on ex-vivo human peripheral blood mononuclear cells (PBMCs), and by in vivo subcutaneous administration. Preliminary in vivo tests demonstrated no hepato-, no nephro- and no genotoxicity in Balb/c mice compared to controls treated with cisplatin. These findings suggest these calixpyrroles might be novel therapeutic tools for the treatment of prostate cancer and of particular interest for the treatment of androgen-independent castration-resistant prostate cancer.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Poríferos
/
Neoplasias de la Próstata Resistentes a la Castración
/
Antineoplásicos
Idioma:
En
Revista:
Invest New Drugs
Año:
2022
Tipo del documento:
Article